相关实验视频

Updated: Jan 8, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

使用NULISA血生物标志物和机器学习的痴呆症病因分类

Kelly N DuBois, Subhamoy Pal, Amanda Cook Maher

medRxiv : the preprint server for health sciences

|December 15, 2025

概括

多重体等离子体蛋白质学和机器学习可以准确地区分痴呆的原因. 这种微创方法有助于诊断复杂的神经退行性疾病,改善患者护理.

科学领域:

神经科学是一个神经科学.
生物标志物发现发现
计算生物学计算生物学

背景情况:

精确的痴呆症亚型的死前诊断具有挑战性,特别是在非典型的呈现时.
多复合性等离子体蛋白质学提供了一种最少的侵入性诊断方法.
机器学习增强了复杂蛋白质组数据的分析.

研究的目的:

评估使用多重血蛋白学与机器学习用于痴呆病因的差异诊断的可行性.
为了确定不同类型痴呆症的血中疾病特异性蛋白质模式.
开发和验证用于预测痴呆症病因的机器学习模型.

主要方法:

从194名参与者的血样本使用NULISA CNS 120+生物标志物面板进行了分析.
鉴定出与阿尔茨海默氏症,前叶退行,利维体病和血管疾病相关的不同丰富的蛋白质.
监督的XGBoost分类器模型被训练并应用于预测轻度认知障碍参与者的病因学.

主要成果:

NULISA 血生物标志物揭示了每个痴呆病因特异性的独特蛋白质模式.
XGBoost分类器准确地区分了痴呆症亚型,具有高特异性.
这些模型在适用于轻度认知障碍病例时,成功产生了强大的病因学预测.

结论:

多复合血蛋白学与机器学习相结合,是诊断复杂痴呆病因的可行方法.
该框架提供了一种基于数据的方法,用于神经退行性疾病的差异诊断.
未来使用更大的队列进行的研究将进一步完善生物标志物识别和诊断准确性.

更多相关视频

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

相关概念视频

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...